Navigation Links
Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
Date:10/13/2011

PALO ALTO, Calif., Oct. 13, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced the initiation of a Phase 2b clinical trial to evaluate Telintra treatment of patients with Low to Intermediate-1 IPSS Risk, transfusion dependent, non-deletion (5q) myelodysplastic syndrome (MDS), who have not been treated with hypomethylating agents (HMA) such as Vidaza® or Dacogen®.  This patient population represents the majority of MDS patients and a significant unmet medical need.  

This multicenter trial is intended to enroll up to 145 evaluable patients with 2 planned interim analyses, the first of which will be performed when data from 49 evaluable patients are available; and the second at 97 evaluable patients. The primary objective of the trial is to determine the hematologic improvement-erythroid response rate as determined by clinically significant transfusion reduction or independence, in accordance with International Working Group MDS criteria (2006). Secondary objectives include determination of response rates of increasing neutrophil and platelet levels, and safety.  Pretreatment bone marrow samples from selected patients may be obtained to confirm genomic results obtained in previous studies.      

In a similar, HMA-naive, transfusion-dependent population of 19 patients, 12 patients (63%) treated with Telintra achieved either clinically significant, according to International Working Group 2006 criteria, transfusion reductions (9 patients), or complete transfusion independence (3 patients), as previously reported in the journal Cancer (Raza, A., et al., doi: 10.1002/cncr.26469, September 1, 2011).  Telintra was also shown to have multilineage responses resulting in improvement in MDS patients who additionally had low levels of neutrophils and/or platelets and, therefore, may offer an advantage in the treatment
'/>"/>

SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
2. Telik Announces First Quarter 2011 Financial Results
3. Telik Announces Presentation of New Data on the Characterization of Novel Ezatiostat (TELINTRA®, TLK199) Analogs at American Association for Cancer Research Annual Meeting
4. Telik Announces Presentation and Webcast at 10th Annual Needham Healthcare Conference
5. Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance
6. Telik Announces Presentation and Webcast at 13th Annual BIO CEO & Investor Conference
7. Telik Announces Presentation at American Society of Hematology Annual Meeting
8. Telik Announces Third Quarter 2010 Financial Results
9. Telik Awarded $1.2 Million in Grants for Qualifying Therapeutic Development Projects
10. Telik Announces Publication of Review Focused on the Inhibition of the Enzyme GSTP1-1 as a Target for New Cancer Treatments
11. Telik Announces Publication of a Case Report of a Sustained Hematologic Response in Myelodysplastic Syndrome Following an Abbreviated Exposure to Oral Telintra(R) (Ezatiostat HCl)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... July 14, 2014  Mylan Inc. (NASDAQ: MYL ... agreement with Abbott (NYSE: ... non-U.S. developed markets specialty and branded generics business ("the ... will receive 105 million shares of the combined ... of $50.20 on Friday, July 11, 2014, representing an approximately ...
(Date:7/11/2014)... , July 11, 2014 Patient ... marketing and, consequently, organizations are turning to an ... As part of this evolving approach ... to educate, communicate and engage patients throughout their ... to patient empowerment. By mapping the patient journey ...
(Date:7/11/2014)... -- Research and Markets  has announced the addition ... report to their offering. ... hollow needle commonly used with a syringe to inject ... from it. A hypodermic needle is used for rapid ... be ingested. Hypodermic needles are broadly classified into non-safety ...
Breaking Medicine Technology:Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 2Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 3Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 4Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 5Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 6Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 7Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 8Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 9Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 10Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 11New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3
... 11, 2010 Thoratec Corporation (Nasdaq: THOR ... therapies to save, support and restore failing hearts, said ... Tuesday, November 16 at the American Heart Association (AHA) ... and chief executive officer of Thoratec, will be discussing ...
... 2010 Ardea Biosciences, Inc. (Nasdaq: RDEA ... trials of BAY 86-9766 (formerly known as RDEA119) will ... and Treatment of Cancer (EORTC) – National Cancer Institute ... on "Molecular Targets and Cancer Therapeutics" in Berlin, Germany. ...
Cached Medicine Technology:Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 3Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 4
(Date:7/14/2014)... The report “Biofertilizers Market ... Type (Cereals & Grains, Pulses & Oilseeds, ... Azospirillium, Cyanobacteria, Phosphate solubilizing bacteria), & by ... 2019” defines and segments the biofertilizers market ... values for the market. It also identifies ...
(Date:7/14/2014)... E.J. Mundell ... News) -- When an 11-year-old boy in San Diego ... the nickel in his family,s iPad. They also ... iPad,s metal surfaces with a form-fitting case. The ... personal effects as potential sources of nickel exposure" and ...
(Date:7/14/2014)... specialists look back on 40 years of the Glasgow Coma ... research and clinical practice, in a new Personal View published ... The Personal View is published on the 40th anniversary of ... Since this seminal publication, the Glasgow Coma Scale has ... conscious level, the clinical hallmark of acute brain injury. The ...
(Date:7/14/2014)... to ignore irrelevant stimuli underlies the impaired working memory ... reports a new study in the current issue of ... good at focusing on the information that we are ... thoughts that aren,t relevant. However, memory impairment in schizophrenia ... this filtering process, which Dr. Teal Eich at Columbia ...
(Date:7/14/2014)... N.J. (PRWEB) July 14, 2014 Documented ... Laurel, has announced the publication of its first military memoir ... crash on Black Thursday in October 1943 and 19 months ... to return home and build the American dream. , ... and the American dream (Amazon) is a true ...
Breaking Medicine News(10 mins):Health News:Biofertilizers Market worth $1,649.7 Million by 2019 - A Report by MarketsandMarkets 2Health News:Biofertilizers Market worth $1,649.7 Million by 2019 - A Report by MarketsandMarkets 3Health News:Biofertilizers Market worth $1,649.7 Million by 2019 - A Report by MarketsandMarkets 4Health News:iPads Can Trigger Nickel Allergies in Kids 2Health News:'Noisy' memory in schizophrenia 2Health News:Mount Laurel-based Documented Legacy to Release Military Memoir of World War II Air Force Vet Who Survived Black Thursday Crash 2
... HealthDay Reporter , FRIDAY, March 16 (HealthDay ... for kids who have a genetic predisposition to aggressive ... new research suggests. "There,s an intricate interplay between ... assistant professor of criminology at the University of Texas ...
... Musicians and their instruments often make beautiful music together, but ... of musical instruments may put their owners at risk for ... Contact dermatitis is a rash caused by an irritant or ... components of musical instruments -- such as metals, exotic woods ...
... Obesity appears to significantly increase the risk of death ... mortality even among those prescribed 18 or fewer pills ... as a marker of increased vulnerability," said Robert Langer, ... and Prevention | Nutrition, Physical Activity and Metabolism 2012 ...
... companies in overcoming common issues associated with crystal formation ... The software, which has been developed at the University ... Centre (CCDC) is called Visual HABIT. It offers a ... companies to adopt a more ,bottom up, approach to ...
... , FRIDAY, March 16 (HealthDay News) -- People with ... risk for health problems that affect the heart, an ... of psoriasis. Chronic inflammation is also a characteristic of ... said Dr. Joel Gelfand, an assistant professor of dermatology ...
... facilitate efficient production of chemicals, materials and fuels from ... Excellence (CoE) in White Biotechnology Green Chemistry Research ... or cell factories, for producing new useful compounds from ... for example, for manufacturing bioplastics or in medical applications. ...
Cached Medicine News:Health News:With Spanking, Nature and Nurture Create More Aggression, Study Suggests 2Health News:With Spanking, Nature and Nurture Create More Aggression, Study Suggests 3Health News:Tooting Your Horn Can Raise Risk for Skin Condition 2Health News:Obesity raises death risk tied to sleeping pills 2Health News:Obesity raises death risk tied to sleeping pills 3Health News:New technology to aid crystallization prediction 2Health News:Psoriasis Patients May Face Higher Heart Risk 2Health News:Novel plastics and textiles from waste with the use of microbes 2